The revised guidelines for making submissions to list drugs on the Australian Pharmaceutical Benefits Scheme have raised industry and patient concerns over the criteria for choosing the comparator drug, how to assess differing levels of evidence, and the need for more patient and clinician input.

A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.

A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.